Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase

Proteins: Structure, Function and Bioinformatics

Volumn 79, Issue 5, 2011, Pages 1573-1588

  Darian, Eva ^a   Guvench, Olgun ^b   Yu, Bing ^c   Qu, Cheng Kui ^c   Mackerell, Alexander D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Department of Pharmaceutical Sciences   (Marshall Islands)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CHARMM; Childhood leukemia; Molecular dynamics; Noonan's syndrome; Normal mode analysis; Phosphatase assay; Potential of mean force

Indexed keywords

ARGININE; PHOSPHOPEPTIDE; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ANIMAL CELL; ARTICLE; ENZYME ACTIVITY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE;

HUMANS; LEUKEMIA; MOLECULAR DYNAMICS SIMULATION; MUTATION; NOONAN SYNDROME; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SRC HOMOLOGY DOMAINS;

EID: 79954624505     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22984     Document Type: Article

References (52)

1. Bennett AM, Hausdorff SF, O'Reilly AM, Freeman RM, Neel BG. Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol Cell Biol 1996; 16: 1189-1202.
2. Xiao S, Rose DW, Sasaoka T, Maegawa H, Burke TRJr, Roller PP, Shoelson SE, Olefsky JM. Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. J Biol Chem 1994; 269: 21244-21248.
3. Rivard N, McKenzie FR, Brondello JM, Pouyssegur J. The phosphotyrosine phosphatase PTP1D, but not PTP1C, is an essential mediator of fibroblast proliferation induced by tyrosine kinase and G protein-coupled receptors. J Biol Chem 1995; 270: 11017-11024.
4. Yu M, Luo J, Yang W, Wang Y, Mizuki M, Kanakura Y, Besmer P, Neel BG, Gu H. The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem 2006; 281: 28615-28626.
5. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003; 28: 284-293.
6. Xu D, Qu CK. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci 2008; 13: 4925-4932.
7. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006; 7: 833-846.
8. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92: 441-450.
9. Eminaga S, Bennett AM. Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation. J Biol Chem 2008; 283: 15328-15338.
10. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29: 465-468.
11. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, Hahlen K, Hasle H, Licht JD, Gelb BD. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148-150.
12. Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M, Palmi C, Carta C, Pession A, Arico M, Masera G, Basso G, Sorcini M, Gelb BD, Biondi A. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004; 104: 307-313.
13. Lechleider RJ, Sugimoto S, Bennett AM, Kashishian AS, Cooper JA, Shoelson SE, Walsh CT, Neel BG. Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor. J Biol Chem 1993; 268: 21478-21481.
14. Sugimoto S, Wandless TJ, Shoelson SE, Neel BG, Walsh CT. Activation of the SH2-containing protein tyrosine phosphatase. SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1 J Biol Chem 1994; 269: 13614-13622.
15. Lee CH, Kominos D, Jacques S, Margolis B, Schlessinger J, Shoelson SE, Kuriyan J. Crystal-structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. Structure 1994; 2: 423-438.
16. Eck MJ, Pluskey S, Trub T, Harrison SC, Shoelson SE. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature 1996; 379: 277-280.
17. Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 1998; 6: 249-254.
18. Guvench O, Qu C-K, MacKerell ADJr. Tyr66 acts as a conformational switch in the closed-to-open transition of the SHP-2 N-SH2-domain phosphotyrosine-peptide binding cleft. BMC Struct Biol 2007; 7: 14.
19. Brooks BR, Brooks CL, 3rd, Mackerell AD, Jr., Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, Hodoscek M, Im W, Kuczera K, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, Post CB, Pu JZ, Schaefer M, Tidor B, Venable RM, Woodcock HL, Wu X, Yang W, York DM, Karplus M. CHARMM: the biomolecular simulation program. J Comput Chem 2009; 30: 1545-1614.
20. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K. Scalable molecular dynamics with NAMD. J Comput Chem 2005; 26: 1781-1802.
21. MacKerell ADJr, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiórkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998; 102: 3586-3616.
22. MacKerell ADJr, Feig M, Brooks CLIII. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem 2004; 25: 1400-1415.
23. Fiser A, Do RKG, Sali A. Modeling of loops in protein structures. Protein Sci 2000; 9: 1753-1773.
24. Sali A, Blundell TL. Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
25. Lovell SC, Word JM, Richardson JS, Richardson DC. The penultimate rotamer library. Proteins 2000; 40: 389-408.
26. Levitt M, Lifson S. Refinement of protein conformations using a macromolecular energy minimization procedure. J Mol Biol 1969; 46: 269-279.
27. Fletcher R, Reeves C. Function minimization by conjugate gradients. Comput J 1964; 7: 149-154.
28. Word JM, Lovell SC, Richardson JS, Richardson DC. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol 1999; 285: 1735-1747.
29. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 79: 926-935.
30. Durell SR, Brooks BR, Ben-Naim A. Solvent-induced forces between two hydrophilic groups. J Phys Chem 1994; 98: 2198-2202.
31. Allen MP, Tildesley DJ. Computer simulation of liquids. Oxford: Oxford University Press; 1987.
32. Darden T, York D, Pedersen L. Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J Chem Phys 1993; 98: 10089-10092.
33. Steinbach PJ, Brooks BR. New spherical-cutoff methods for long-range forces in macromolecular simulation. J Comput Chem 1994; 15: 667-683.
34. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977; 23: 327-341.
35. Hockney RW. The potential calculation and some applications. In: Alder B, Fernbach S, Rotenberg M, editors. Methods in computational physics, Vol. 9. New York: Academic Press; 1970. pp 136-211.
36. Hoover WG. Canonical dynamics: equilibrium phase-space distributions. Phys Rev A 1985; 31: 1695-1697.
37. Nosé S. A molecular dynamics method for simulations in the canonical ensemble. Mol Phys 1984; 52: 255-268.
38. Feller SE, Zhang YH, Pastor RW, Brooks BR. Constant pressure molecular dynamics simulation: the Langevin piston method. J Chem Phys 1995; 103: 4613-4621.
39. Kumar S, Bouzida D, Swendsen RH, Kollman PA, Rosenberg JM. The weighted histogram analysis method for free-energy calculations on biomolecules. I. The method. J Comput Chem 1992; 13: 1011-1021.
40. Grossfield A. "WHAM: the weighted histogram analysis method", Version 2.0.3
41. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA, Neel BG. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004; 10: 849-857.
42. Zhao Z, Larocque R, Ho WT, Fischer EH, Shen SH. Purification and characterization of PTP2C, a widely distributed protein tyrosine phosphatase containing two SH2 domains. J Biol Chem 1994; 269: 8780-8785.
43. Qu CK, Shi ZQ, Shen R, Tsai FY, Orkin SH, Feng GS. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol Cell Biol 1997; 17: 5499-5507.
44. Banavali NK, Roux B. The N-terminal end of the catalytic domain of SRC kinase Hck is a conformational switch implicated in long-range allosteric regulation. Structure 2005; 13: 1715-1723.
45. Huang N, Banavali NK, MacKerell ADJr. Protein-facilitated base flipping in DNA by cytosine-5-methyltransferase. Proc Natl Acad Sci USA 2003; 100: 68-73.
46. Priyakumar UD, Mackerell ADJr. NMR imino proton exchange experiments on duplex DNA primarily monitor the opening of purine bases. J Am Chem Soc 2006; 128: 678-679.
47. Jia Z, Barford D, Flint AJ, Tonks NK. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science 1995; 268: 1754-1758.
48. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 2006; 281: 6785-6792.
49. Sugimoto S, Lechleider RJ, Shoelson SE, Neel BG, Walsh CT. Expression, purification, and characterization of SH2-containing protein tyrosine phosphatase, SH-PTP2. J Biol Chem 1993; 268: 22771-22776.
50. Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 1998; 6: 249-254.
51. Pei D, Wang J, Walsh CT. Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1. Proc Natl Acad Sci USA 1996; 93: 1141-1145.
52. Cunnick JM, Mei L, Doupnik CA, Wu J. Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2. J Biol Chem 2001; 276: 24380-24387.